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Genetically engineered mouse models are powerful systems for dissecting the process of human leukemo-
genesis. In this issue of Cell Stem Cell, Schindler et al. (2009) describe the elegant use of this approach to
dissect, but not completely replicate, the multistep pathogenesis of TEL-AML1+ leukemia.Much evidence now indicates that many
human leukemias are the end result of
a complex process that involves the
cumulative acquisition of multiple rare
mutations that may extend over a period
of several years. This concept provides
a potential explanation for the phenotypic
diversity these diseases display even
when they share certain features and/or
a common underlying chromosomal ab-
normality. If correct, this heterogeneity
will pose significant challenges to the
development of effective therapies that
target key components of the leukemo-
genic process in large groups of patients.
Accordingly,much interest is now focused
on delineating the extent of this diversity
and the identification of shared or conver-
gent pathways that might be targeted.
Genetically engineered mouse models
designed to mimic the human leukemo-
genic process and allow each step to be
investigated separately are thus increas-
ingly attractive experimental paradigms,
as these offer the possibility of also
controlling the timeandcell target inwhich
defined perturbations are introduced in
a reproducible fashion.
In this regard, the study by Schindler
et al. (2009) published in this issue
provides a lead example of the power of
this approach—here applied to an exami-
nation of the role of the fusion gene TEL-
AML1, which is a frequent hallmark of
acute lymphoid leukemia (ALL) in children
but rarely in adults (Greaves andWiemels,
2003). The TEL-AML1 fusion gene con-
sists of the 50 end of the ETS family gene
TEL (or ETV6) juxtaposed adjacent to
the 30 end of the AML1 (RUNX1) gene
that encodes a DNA-binding subunit of
the transcriptional regulator core-binding
factor (CBF). In patients, this transloca-
tion is detected in leukemic blasts that
appear to be blocked at an early stage of
B-lymphoid lineage differentiation. Theresultant abnormal accumulation of
TEL-AML1-positive lymphoblasts and
the failure to detect TEL-AML1-positive
malignant cells in more primitive compart-
ments or other hematopoietic lineages are
the basis of the disease classification as
ALL and its hypothesized origin in a
B-lymphoid-restricted precursor (Castor
et al., 2005). However, the findings that
can be gleaned from such cell population
analyses are necessarily limited to the
detection of highly amplified clones of
TEL-AML1 cells, which may not develop
until the cells within the clone have
reached a particular stage of differentia-
tion. Interestingly, there is recent evidence
that this downstream expansion may well
be the case in TEL-AML1-positive ALL in
children due to its multistep pathogenesis
(Hong et al., 2008).
The biological effects of TEL-AML1
expression in hematopoietic stem cells
as well as the various early stages of
differentiation of B-lineage cells has also
been studied previously in several exper-
imental systems. This existing literature
Figure 1. A Mouse Model for the TEL-AML1 Fusion Gene as an Initiating Event in Acute
Lymphoid Leukemia
The studies of Schindler et al. (2009) describe the features of a new, genetically engineered mouse model
of TEL-AML1 leukemia. Thismodel appears tomimic themultistep process of leukemogenesis that occurs
in children more closely than previously generated models. In this new mouse model, over time, expres-
sion of TEL-AML1 causes the stem cell and myeloid progenitor compartments to become selectively and
markedly amplified. However, as appears to be the case in humans (Hong et al., 2008), the introduced
expression of TEL-AML1 alone does not translate into an increase in the output of mature blood cells
or to the emergence of leukemic clones until after a second hit is delivered. In the mice, this is achieved
experimentally by exposing the cells to a nonspecific mutagenic agent (N-ethyl-N-nitrosourea [ENU]). In
humans, the cause and nature of the second hit is not known. Nevertheless, the mouse model is not
perfect, as the leukemias produced are T-lineage acute lymphoid leukemias (T-ALLs), whereas those
obtained in children are exclusively B-ALLs.Cell Stem Cell 5, July 2, 2009 ª2009 Elsevier Inc. 5
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Previewsis also confusing, likely due at least in part
to the use of cells from different species,
from different hematopoietic compart-
ments, from different stages of ontogeny,
and expressing the TEL-AML1 gene
under the control of different regulatory
elements, none of which used the endog-
enous TEL promoter. The novel aspect of
the present study from the Hock labora-
tory (Schindler et al., 2009) is the adoption
of a genetic engineering strategy that
does employ the endogenous TEL
promoter, in addition to the use of
different strategies that allowed targeting
the expression of TEL-AML1 to hemato-
poietic stem cells and hence all their
derivatives. Examination of the hemato-
poietic system of conditionally targeted
mice (using Mx-Cre activated by polyIC
injection) revealed the stem cell and
myeloid progenitor compartments to
be significantly expanded, although the
output of mature myeloid cells was
not enhanced, and lymphopoiesis was
consistently and selectively compro-
mised from an early stage.Stem Cell Aging a
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Stem cells age, but the underlying
colleagues (2009) show that DNA d
melanocyte stem cells by inducing
Agingcanbedescribedasamultisystemic
problem impairing overall fitness. As hu-
mans age, wounds heal more slowly, hair
grays, muscle strength diminishes, and
certain aspects of neurological function
decline. Changes in tissue function with
aging suggested that the aging problem
may lie, in part, with multipotent stem
cells, which have been identified in many
adult tissues, including blood, brain, mu-
6 Cell Stem Cell 5, July 2, 2009 ª2009 ElsevInterestingly, after the mice were
treated with a potent but nonspecific
mutagen (ENU), leukemogenesis was
markedly accelerated and enhanced
in the TEL-AML1 mice as compared to
their normal counterparts. This finding
suggests that the model may recapitulate
the presumed multistep features of TEL-
AML1 ALL pathogenesis in children
(Figure 1). At the same time, the model is
clearly not yet ideal, in that the diseases
obtained in the mice were primarily T-
lineage leukemias rather than B-lineage
leukemias, the latter being the type that
appears exclusively in human cells that
have acquired the TEL-AML1 gene.
Further studies will clearly be needed to
determine the underlying explanation for
this difference and its significance. Possi-
bilities include peculiarities associated
with the experimental use of ENU to
initiate a second ‘‘hit,’’ innate differences
in the early stages of murine and human
lymphopoiesis, and the need to use
embryonic or neonatal mice for induction
of the second hit. Recent data indicatend Aberrant
in the Niche
ord, CA 94305, USA
mechanisms remain unclear. In a
amage, a prime suspect in stem cell
premature differentiation, without ind
scle, skin, intestine, and gonads (Morrison
and Spradling, 2008). Adult tissue stem
cells fuel the renewal of many tissues
through the regulated generation of in-
creasingly committed progenitor cells and
ultimately terminally differentiated cells
that execute specific aspects of tissue
function.However, how somatic stemcells
change with aging is only beginning to be
understood.
ier Inc.that the lineage preferences of stem
cells change dramatically during early
life (Dykstra et al., 2007), and hence closer
attention to the ontological status of
the ultimately targeted cell may prove
to be a more important variable than
anticipated.
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Reduced regenerative capacity might
suggest that tissue stem cells diminish in
number with advancing age; however,
this trend is not universally the case.
Neural progenitors show diminished num-
bers and impaired proliferative potential
with aging. Melanocyte stem cells, which
give rise to differentiated melanocytes
within the hair follicle, are significantly
depleted in number with aging and in
